• Test Code:
    5120 (Sequencing)7600 (FISH Panel)81445
  • Department:
  • Test Synonyms:
    Lung Cancer PanelAmpliSeq NSCLC PanelIon Torrent Lung PanelAKT1ALKBRAFCDKN2ADDR2EGFRERBB2HRASJAK2KDRKRASMAP2K1NOTCH1NRASNTRK1NTRK2NTRK3PIK3CAPIK3R1PIK3R2PTENPTPRDTP53ROS1RETMET
  • CPT Code(s):
    81450
Background:

Screening for mutations in oncogenes and tumor suppressor genes is increasingly important in delivering personalized cancer care. The GeneTrails® NSCLC Panel delivers information on a variety of treatment-informative mutations in the 23 genes listed below, which are known to play a role in cases of non-small cell lung cancer.  The next-gen sequencing panel has a sensitivity of ≤10% mutant allele.
 

 AKT1  DDR2  JAK2  NOTCH1  NTRK3  PTEN
 ALK*  EGFR  KDR  NRAS  PIK3CA  PTPRD
 BRAF  ERBB2  KRAS  NTRK1  PIK3R1  TP53
 CDKN2A  HRAS  MAP2K1  NTRK2  PIK3R2  

 * Does not cover ALK translocations; separate FISH test required

In addition to the sequencing panel, tumor samples can be screened by FISH for translocations involving the ALK, ROS1 or RET kinase genes, and for MET gene amplification.  This FISH panel may be added to the sequencing panel by ordering both test codes 5120 and 7600.   The FISH probes may be ordered individually as well:  ALK (test code 8019), ROS1 (test code 8720), RET (test code 8700) and MET (test code 8500).

Recommended Use:
The GeneTrails® NSCLC Panel is well-suited for screening potentially actionable mutations in the non-small cell lung carcinomas, including adenocarcinomas, squamous cell carcinomas, and large cell undifferentiated carcinomas.

Methodology:

The GeneTrails® NSCLC Panel is performed on DNA from formalin-fixed, paraffin-embedded (FFPE) tumor tissue using next-generation, semiconductor-based sequencing (Ion Torrent platform). Input DNA is amplified using the AmpliSeq technology (Ion Torrent), after which the amplicons are modified with adaptors, re-amplified, and subjected to emulsion PCR. The final products are sequenced on a semiconductor-based chip.

  • Input DNA: 20 ng

Specimen Requirements:

Includes 5 slides for FISH:

  • A paraffin block or
  • 15 unstained sections of tumor (4-5 microns) (15 sections for small biopsies).
Contact Client Services for shipping materials and procedures at (855) 535-1522.


A REQUISITION FORM MUST ACCOMPANY ALL SAMPLES.  Please include detailed clinical information.

         

Test Performed (Days):

Sequencing: Twice per week, FISH: Mon - Sat

Turn Around Time:

Sequencing: 10 - 14 days, FISH: 3 - 7 days

Shipment Sensitivity Requirements:

  • Keep specimen cool during transit. Do not ship on dry ice.
  • Please use the cold pack provided in the KDL shipping kit.
  • Ship the specimen overnight express, using the FedEx priority overnight label provided. 
  • Contact Client Services for shipping materials and procedures at (855) 535-1522.

References:

  1. Linardou H, Dahabreh IJ, Bafaloukos D, Kosmidis P, Murray S. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol. 2009 Jun;6(6):352-66.
  2. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011 Feb;12(2):175-80.

Additional Info:

The GeneTrails® NSCLC Panel is well-suited for screening potentially actionable mutations in the non-small cell lung carcinomas, including adenocarcinomas, squamous cell carcinomas, and large cell undifferentiated carcinomas.

The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials.

Learn More